ClinicalTrials.Veeva

Menu

A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants

Lilly logo

Lilly

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Drug: LOXO-783
Drug: Cholestyramine

Study type

Interventional

Funder types

Industry

Identifiers

NCT05894928
LOXO-PIK-23009
J4C-OX-JZUD (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to conduct blood tests to measure how much LOXO-783 is in the bloodstream and how the body handles and eliminates LOXO-783 when administered alone or in combination with cholestyramine in healthy participants. The study will also evaluate the safety and tolerability of LOXO-783 with and without cholestyramine. Participation could last up to 63 days including screening period.

Enrollment

21 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy status as defined by the absence of evidence of any clinically significant active or chronic disease
  • Body mass index (BMI): 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive

Exclusion criteria

  • Females who are lactating or of childbearing potential
  • Clinically significant history of any drug sensitivity, drug allergy, or food allergy

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

21 participants in 3 patient groups

LOXO-783 alone
Experimental group
Description:
Single dose of LOXO-783 administered orally.
Treatment:
Drug: LOXO-783
LOXO-783 + Cholestyramine 1 hour post dose
Experimental group
Description:
Single dose of LOXO-783 administered orally followed by a single dose of cholestyramine administered orally after 1 hour.
Treatment:
Drug: Cholestyramine
Drug: LOXO-783
LOXO-783 + Cholestyramine 4 hours post dose
Experimental group
Description:
Single dose of LOXO-783 administered orally followed by a single dose of cholestyramine administered orally after 4 hours.
Treatment:
Drug: Cholestyramine
Drug: LOXO-783

Trial contacts and locations

1

Loading...

Central trial contact

Patient Advocacy

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems